AZTherapies Announces Appointment of Pharma Industry Veteran George D. Behrakis to its Board of Directors
Retrieved on:
Wednesday, August 7, 2019
David R. Elmaleh, Ph.D., Founder, CEO, and Chairman of AZTherapies commented on the appointment: We are pleased to welcome George to our Board.
Key Points:
- David R. Elmaleh, Ph.D., Founder, CEO, and Chairman of AZTherapies commented on the appointment: We are pleased to welcome George to our Board.
- A former pharmacist and pharmaceutical innovator, Mr. Behrakis is well known in the industry for his contributions to the successful development and commercial launch of Tylenol while at Johnson & Johnson.
- Mr. Behrakis is the former Vice Chair of the Board of Northeastern University, and former Board member of Brigham and Womens Hospital and Tufts Medical Center.
- AZTherapies is increasingly being recognized for its innovative approach to Alzheimers and other neurodegenerative diseases, said Mr. Behrakis.